-+ 0.00%
-+ 0.00%
-+ 0.00%

Assembly Bio Q2 FY26 net loss narrows to $3.86 million; revenue rises to $13.37 million

PUBT·08/13/2026 20:00:51
Listen to the news
Assembly Bio Q2 FY26 net loss narrows to $3.86 million; revenue rises to $13.37 million
  • Assembly Biosciences posted a GAAP net loss attributable to common stockholders of USD 3.9 million, or USD 0.20 a share, in Q2 2026.
  • Revenue rose 39.01% year over year to USD 13.4 million, including a USD 5.1 million cumulative catch-up adjustment.
  • Research and development expenses fell 7.51% to USD 14.9 million; general and administrative costs increased 4.51% to USD 4.8 million.
  • Cash, cash equivalents and marketable securities climbed to USD 320.4 million at June 30, extending projected runway into 2029.
  • Pipeline plans include ABI-6250 Phase 2 starts in chronic HDV by year-end 2026 and in PBC/PSC in Q1 2027; Gilead targets GS-1179 Phase 2 by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131600PRIMZONEFULLFEED9809750) on August 13, 2026, and is solely responsible for the information contained therein.